top of page
Back to plaque
Alzheimer’s Disease is an asteroid headed directly at Earth. An astonishing 1 in 4 Americans are expected to develop this devastating...
0 comments
A tissue a tasket
It seems like an obvious concept: Let's say you are developing a drug that works by inhibiting, say, phosphodiesterase-4 (PDE-4) to treat...
0 comments
Meh-dicine
The holy grail of the pharma industry is FDA approval, but the final clue may be positive top-line (Phase III) results. However, it is...
0 comments
Screen saviors
High-throughput screening (HTS) has been a blessing and a curse. A blessing in codifying a straightforward approach to discovering drug...
0 comments
Compound problem
Where to even begin? A mold flew in through the window and, presto, penicillin. Hey, then, why not screen all the compounds we have on...
0 comments
Stop culture
We waited a long time for a real gene therapy, though we were promised it would be easy. So now we are feeling optimistic about the other...
0 comments
Leper known
The story begins in the 1950s when thalidomide was approved as an over the counter sedative in Europe, but conspicuously rejected by the...
0 comments
Heart breaker
Small molecule chemical antibiotics are among the most prescribed drugs in the world, and few individuals in the first world can say they...
0 comments
Model mayhem
Martin Karplus of Harvard, Michael Levitt of Stanford and Arieh Warshel of USC were awarded the Nobel Prize in Chemistry in 2013 for...
0 comments
No holds–barred!
Clinical holds are lost battles in the war against drug attrition. The process of drug development critically revolves around the FDA’s...
0 comments
Blog: Blog
bottom of page